Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olinvacimab plus capecitabine in metastatic colorectal carcinoma after failure of two prior chemotherapies
KCT0005889Phase 2Not yet recruiting
- Sponsor
- Ministry of Health & Welfare
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olinvacimab and capecitabine in colorectal cancer (CRC), sponsored by Ministry of Health & Welfare. Primary endpoints: Safety and tolerability of olinvacimab plus capecitabine and Efficacy of olinvacimab plus capecitabine. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
olinvacimabcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on KCT0005889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005889.